DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.
Yonghan HeRaphael KochVivekananda BudamaguntaPeiyi ZhangXuan ZhangSajid KhanDinesh ThummuriYuma T OrtizXin ZhangDongwen LvJanet S WiegandWen LiAdam C PalmerGuangrong ZhengDavid M WeinstockDaohong ZhouPublished in: Journal of hematology & oncology (2020)
These findings support the clinical testing of DT2216 in patients with Bcl-xL-dependent TCLs, both as a single agent and in rational combinations.
Keyphrases